Candriam S.C.A. Rapt Therapeutics, Inc. Transaction History

Candriam S.C.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$16.06 - $21.61 $275,220 - $370,330	-17,137 Reduced 5.19%	313,262 $5.86 Million
Q1 2023 May 12, 2023	BUY	$17.19 - $30.8 $294,585 - $527,819	17,137 Added 5.47%	330,399 $6.06 Million
Q3 2022 Nov 10, 2022	BUY	$17.96 - $30.46 $877,830 - $1.49 Million	48,877 Added 18.49%	313,262 $7.54 Million
Q2 2022 Aug 03, 2022	BUY	$10.26 - $23.59 $1.09 Million - $2.52 Million	106,621 Added 67.58%	264,385 $4.83 Million
Q1 2022 May 13, 2022	BUY	$17.02 - $40.22 $2.69 Million - $6.35 Million	157,764 New	157,764 $3.47 Million

104

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $26.1M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.